Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Pediatric Ophthalmology · MSMO1 Deficiency and GLS-Related Disorders

Current Standard of Care and Symptom Management

At a Glance

Care for MSMO1 deficiency and GLS variants centers on prompt, individualized cataract care, lifelong eye monitoring, seizure treatment, and developmental therapies. Cholesterol and statin approaches are off-label, while GLS inhibitors remain limited to laboratory and animal research.

When managing an ultra-rare metabolic disorder, care is divided into two parts: standard surgical and neurological support, and experimental metabolic treatments. Because these conditions are so rare, there is no “rulebook,” but doctors follow established guidelines for managing the individual symptoms.

Evidence Level Guide:

  • Established Practice: Cataract surgery, glaucoma surveillance, seizure management, physical/occupational therapy.
  • Off-Label/Case Report: Oral statins/cholesterol and compounded topical creams for MSMO1.
  • Preclinical: GLS inhibitors (CB-839) tested only in animal models.

Vision Care: Timing is Critical

The most urgent part of care is often managing the infantile cataracts. The lens must be clear for the brain to learn how to see. If the brain does not receive clear images during the first few months of life, it may never develop normal vision—a condition called amblyopia [1].

  • Surgical Window: Surgery timing depends on whether the visual axis is obstructed, cataract density and laterality, retinal status, and the surgeon’s protocol. It requires prompt pediatric ophthalmology assessment and individualized timing [1][2].
  • Post-Surgical Monitoring: Surgery is only the first step. Children need lifelong follow-up to check for glaucoma (high eye pressure), which is a common complication after infant eye surgery [3][4].
  • Visual Correction: After surgery, your child will need immediate correction with aphakic contact lenses or glasses to focus light, followed by “patching” therapy to strengthen the eyes [5][6].

Metabolic Management for MSMO1 Deficiency

For children with MSMO1 deficiency, the goal in experimental care is to bypass the metabolic “roadblock”. These approaches are based entirely on small case reports or series with variable response, are considered off-label, and have no established benefit for cataracts or neurodevelopment.

  • Combination Therapy: Case reports show use of a combination of oral cholesterol supplements and statins (like simvastatin) [7][8]. While statins are usually for high cholesterol, here they are used off-label to slow down the production of the “unfinished” sterols [7].
  • Skin Support: Specialized topical cholesterol and statin creams applied directly to the skin have been described in reports to clear the red, scaly patches (psoriasiform dermatitis) [7][8]. Do not obtain or apply compounded treatments without the treating team’s oversight.
  • Monitoring: Because these treatments are powerful, your doctor will regularly check liver enzymes and creatine kinase (CK) [8].

Managing Glutamate in GLS Variants

There is currently no approved drug that “fixes” the overactive GLS enzyme in humans, and no clinically validated GLS-directed therapy exists.

  • Seizure Management: If your child has epilepsy, a pediatric neurologist will use standard anti-seizure medications tailored to the child’s specific seizure type [9][10].
  • Experimental Research: Scientists have studied GLS inhibitors (like Telaglenastat/CB-839) in labs, finding they alleviated cataracts in zebrafish [10][11]. This is strictly preclinical evidence, not a demonstrated treatment outcome in children.

Surveillance: An Illustrative Example

A child with these symptoms needs a coordinated “home base”. Fixed intervals vary by patient; this is merely an example of what to expect:

  • Ophthalmology: Frequent checks for eye pressure (glaucoma), visual acuity, and lens clarity [4].
  • Metabolic Genetics: Sterol profiles, amino acids, growth, and liver function as dictated by therapy [7]. Repeat MRS is not routine unless a specialist has a specific indication.
  • Neurology: EEG for seizure activity and developmental milestones [10].
  • Early Intervention: Physical, occupational, and speech therapy for developmental support [7].

Common questions in this guide

How quickly should an infant with a cataract be evaluated?
A child with an infantile cataract should be assessed promptly by a pediatric ophthalmologist. Whether surgery is needed and when it should occur depends on whether the cataract blocks the central path of light, its density, whether one or both eyes are affected, retinal health, and the surgeon’s plan. Early clear images help the developing brain learn to see.
What care is needed after infantile cataract surgery?
Surgery is not the end of care. Children usually need contact lenses or glasses to focus light, patching when recommended, and lifelong checks of eye pressure and vision because glaucoma can develop after infant eye surgery.
Are cholesterol supplements and statins proven for MSMO1 deficiency?
Small case reports describe oral cholesterol with a statin such as simvastatin, but this approach is off-label and has no established benefit for cataracts or neurodevelopment. Treatment requires specialist oversight and regular tests of liver enzymes and creatine kinase (CK).
Can creams treat the skin changes linked to MSMO1 deficiency?
Reports have described compounded cholesterol and statin creams improving red, scaly skin patches. These products should not be obtained or applied without the treating team’s supervision because their benefit and safety are not established.
Is there a treatment to correct excess glutamate in GLS variants?
There is no approved or clinically validated medicine that corrects the overactive GLS enzyme in people. GLS inhibitors such as telaglenastat (CB-839) have shown effects only in laboratory or animal studies, so they are not proven treatments for children.
How are seizures and developmental difficulties managed in GLS-related disorders?
A pediatric neurologist chooses standard anti-seizure medicine based on the child’s seizure type and needs. Physical, occupational, and speech therapy, along with monitoring developmental milestones, can provide additional support.
What monitoring should a child with these disorders receive?
Follow-up is individualized but may involve pediatric ophthalmology for eye pressure and vision, metabolic genetics for sterol and amino-acid testing and liver function, neurology for seizures and development, and early-intervention therapies. Repeat brain MRS is not routine unless a specialist has a specific reason.

Get notified when new evidence is published on infantile cataract, skin abnormalities, glutamate excess, and impaired intellectual development.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (11)
  1. 1

    Congenital Cataract Screening.

    Rajavi Z, Sabbaghi H

    Journal of ophthalmic & vision research 2016; (11(3)):310-2 doi:10.4103/2008-322X.188389.

    PMID: 27621790
  2. 2

    Postoperative amblyopia in children with congenital cataracts: a systematic review and meta-analysis.

    Hailaiti A, Yu X, Yao K, Shentu X

    Italian journal of pediatrics 2025; (51(1)):141 doi:10.1186/s13052-025-02010-x.

    PMID: 40390126
  3. 3

    Updates on managements of pediatric cataract.

    Mohammadpour M, Shaabani A, Sahraian A, et al.

    Journal of current ophthalmology 2019; (31(2)):118-126 doi:10.1016/j.joco.2018.11.005.

    PMID: 31317088
  4. 4

    Incidence and Risk Factors of Early-onset Glaucoma following Pediatric Cataract Surgery in Egyptian Children: One-year Study.

    I Gawdat G, M Youssef M, M Bahgat N, et al.

    Journal of current glaucoma practice 2017; (11(3)):80-85 doi:10.5005/jp-journals-10028-1229.

    PMID: 29151681
  5. 5

    Current management of infantile cataracts.

    Lenhart PD, Lambert SR

    Survey of ophthalmology 2022; (67(5)):1476-1505 doi:10.1016/j.survophthal.2022.03.005.

    PMID: 35307324
  6. 6

    Clinical Features and Outcomes of Congenital Cataract Surgery with Primary Intraocular Lens Implantation in a Tunisian Cohort.

    Malek I, Sayadi J, Sammouda T, et al.

    Journal of current ophthalmology 2022; (34(2)):187-193 doi:10.4103/joco.joco_273_21.

    PMID: 36147275
  7. 7

    MSMO1 deficiency: a potentially partially treatable, ultrarare neurodevelopmental disorder with psoriasiform dermatitis, alopecia and polydactyly.

    Tkemaladze T, Bratland E, Bregvadze K, et al.

    Clinical dysmorphology 2023; (32(3)):97-105 doi:10.1097/MCD.0000000000000461.

    PMID: 37195326
  8. 8

    New Homozygous Missense MSMO1 Mutation in Two Siblings with SC4MOL Deficiency Presenting with Psoriasiform Dermatitis.

    Kalay Yildizhan I, Gökpınar İli E, Onoufriadis A, et al.

    Cytogenetic and genome research 2020; (160(9)):523-530 doi:10.1159/000511126.

    PMID: 33161406
  9. 9

    Structure and enzymology of glutaminase S482C and H461L variants associated with excess brain glutamate and neurological disease.

    Crane CS, McIssac TK, Milano SK, et al.

    The Journal of biological chemistry 2026; (302(6)):113091 doi:10.1016/j.jbc.2026.113091.

    PMID: 42055345
  10. 10

    GLS hyperactivity causes glutamate excess, infantile cataract and profound developmental delay.

    Rumping L, Tessadori F, Pouwels PJW, et al.

    Human molecular genetics 2019; (28(1)):96-104 doi:10.1093/hmg/ddy330.

    PMID: 30239721
  11. 11

    Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.

    Gregory MA, Nemkov T, Reisz JA, et al.

    Experimental hematology 2018; (58()):52-58 doi:10.1016/j.exphem.2017.09.007.

    PMID: 28947392

This page is for informational purposes only and does not constitute medical advice. It summarizes established, off-label, and experimental care for children with MSMO1 deficiency or GLS variants; pediatric specialists should guide treatment decisions.